Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma-Bio ServPBSV -27.16%43 ROC (Joel Greenblatt) % is 59.03% as of Apr. 2026, which is 605% above its 10-year median of 8.37. GuruFocus rates PBSV with a GF Score™ of 43/100 and a GF Value™ of $0.58 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 666 Healthcare Providers & Services companies, Pharma-Bio Serv ranks worse than 78.38% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Pharma-Bio Serv's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was 59.03%.
The historical rank and industry rank for Pharma-Bio Serv's ROC (Joel Greenblatt) % or its related term are showing as below:
PBSV'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -61.77 Med: 8.37 Max: 36.89
Current: -35.55
During the past 13 years, Pharma-Bio Serv's highest ROC (Joel Greenblatt) % was 36.89%. The lowest was -61.77%. And the median was 8.37%.
PBSV's ROC (Joel Greenblatt) % is ranked worse than 78.38% of 666
companies
in the Healthcare Providers & Services industry
Industry Median: 12.49
vs PBSV: -35.55
Pharma-Bio Serv's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Pharma-Bio Serv ROC (Joel Greenblatt) % Related Terms
Pharma-Bio Serv ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Pharma-Bio Serv's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBSV vs MGRX, BFRG, VYND: ROC (Joel Greenblatt) % Comparison
For the Health Information Services subindustry, Pharma-Bio Serv's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma-Bio Serv ROC (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Pharma-Bio Serv's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 59.03% mean?
Pharma-Bio Serv (PBSV) has a ROC (Joel Greenblatt) % of 59.03% as of Apr. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Pharma-Bio Serv and its competitors. This is 605% above median its historical median of 8.37. According to the industry distribution chart, Pharma-Bio Serv ranks #522 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 78.4%.
Is Pharma-Bio Serv's ROC (Joel Greenblatt) % too high?
Pharma-Bio Serv's current ROC (Joel Greenblatt) % of 59.03% is 605% above median its 10-year median of 8.37. The Healthcare Providers & Services industry median ROC (Joel Greenblatt) % is 12.49. Pharma-Bio Serv's value of 59.03% is 372.6% above this industry median. Based on the distribution chart, Pharma-Bio Serv ranks #522 out of 666 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Pharma-Bio Serv has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma-Bio Serv's ROC (Joel Greenblatt) % compare to MGRX and BFRG?
According to the Healthcare Providers & Services industry distribution chart, Pharma-Bio Serv ranks #522 out of 666 companies for ROC (Joel Greenblatt) %. This places Pharma-Bio Serv in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 12.49. Pharma-Bio Serv's value of 59.03% is 372.6% above this benchmark. While the company's 10-year median is 8.37 vs. the industry median of 12.49, Pharma-Bio Serv has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median ROC (Joel Greenblatt) % among Healthcare Providers & Services companies is 12.49, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma-Bio Serv's current ROC (Joel Greenblatt) % of 59.03% is 372.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Pharma-Bio Serv and its competitors. For the Healthcare Providers & Services industry, the median ROC (Joel Greenblatt) % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma-Bio Serv's current ROC (Joel Greenblatt) % is 59.03%, which is 605% above median its own 10-year median of 8.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma-Bio Serv stock overvalued right now?
Based on GuruFocus' analysis, Pharma-Bio Serv (PBSV) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.58, compared to a current price of $0.42 — trading 27.2% below its estimated fair value. The current ROC (Joel Greenblatt) % is 59.03%, which is 605% above median its 10-year median of 8.37 and 372.6% above the Healthcare Providers & Services industry median of 12.49. Pharma-Bio Serv's overall GF Score™ is 43/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Pharma-Bio Serv (PBSV), the current ROC (Joel Greenblatt) % is 59.03% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma-Bio Serv (PBSV) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma-Bio Serv stock appears to be undervalued.
The current stock price of $0.42 is trading 27.2% below its estimated GF Value™ of $0.58.
GuruFocus considers Pharma-Bio Serv to be Modestly Undervalued.
Key valuation signals for PBSV:
ROC (Joel Greenblatt) %: 59.03% (605% above median its 10-year median of 8.37)
GF Value™: $0.58 vs. price of $0.42 (27.2% below fair value)
Industry Position: 372.6% above the Healthcare Providers & Services median (#522 of 666)
No single metric tells the full story. See the PBSV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma-Bio Serv Inc is a compliance and technology transfer services consulting firm. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It has three reportable segments: Puerto Rico technical compliance consulting which is the key revenue driver; United States technical compliance consulting; and Europe technical compliance consulting. The company offers solutions to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. It generates maximum revenue from Puerto Rico and also has its presence in United States, Europe and Other countries.
43GF Score
Get the complete analysis for PBSV
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBSV has been successfully added to your 
